skip to main content

OVHIPEC Ovarian — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersOVHIPEC OvarianSCE Medical Oncology

A 60-year-old woman with recurrent ovarian cancer undergoes CRS + HIPEC. The OVHIPEC-1 trial evaluated this approach. What was the main finding?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — HIPEC added to interval cytoreductive surgery

OVHIPEC-1 (van Driel et al NEJM 2018) randomised stage III EOC patients to interval CRS alone vs CRS + HIPEC (cisplatin 100 mg/m² at 40°C for 90 minutes) after 3 cycles of NACT. RFS improved (14.2 vs 10.7 months) and OS improved (45.7 vs 33.9 months). However, results are debated: single-centre trial, open-label, and OVHIPEC-2 (evaluating in front-line) is ongoing. Current guidelines consider HIPEC in interval debulking setting at experienced centres. It is NOT standard for primary debulking or recurrent disease outside trials.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer